| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/12/2001 | US6245737 Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins |
| 06/12/2001 | US6245568 Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| 06/12/2001 | US6245503 Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| 06/12/2001 | US6245502 Target system |
| 06/12/2001 | US6245362 Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication |
| 06/12/2001 | US6245338 OMP26 antigen from Haemophilus influenzae |
| 06/12/2001 | US6245337 Haemophilus adherence and penetration proteins |
| 06/12/2001 | US6245335 Choline binding proteins for anti-pneumococcal vaccines |
| 06/12/2001 | US6245332 Modulation of systemic memory T cell trafficking |
| 06/12/2001 | CA2072123C Inhibitors of purine nucleoside phosphorylase |
| 06/12/2001 | CA2046002C Purinyl and pyrimidinyl tetrahydrofurans |
| 06/10/2001 | CA2327946A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/10/2001 | CA2327925A1 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/07/2001 | WO2001040521A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 06/07/2001 | WO2001040499A2 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses |
| 06/07/2001 | WO2001040497A2 Method for obtaining nucleic acids from an environment sample |
| 06/07/2001 | WO2001040474A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/07/2001 | WO2001040473A2 Pseudomonas aeruginosa antigens |
| 06/07/2001 | WO2001040472A2 Streptococcus pneumoniae antigens |
| 06/07/2001 | WO2001040471A1 Antigenic protein lppq of mycoplasma mycoidessubsp.(mycoides)sc., its preparation and use |
| 06/07/2001 | WO2001040456A1 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | WO2001040451A2 Masp-3, a complement-fixing enzyme, and uses for it |
| 06/07/2001 | WO2001040442A1 Novel bacterial isolate and the preparation and use of its active metabolites |
| 06/07/2001 | WO2001040282A1 Compositions isolated from m. vaccae and their use in the modulation of immune responses |
| 06/07/2001 | WO2001040279A2 Hbv sequences |
| 06/07/2001 | WO2001040262A1 Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease |
| 06/07/2001 | WO2001040242A2 6-o-methylerythromycin a crystal form iii |
| 06/07/2001 | WO2001040241A2 6-o-alkyl-2-nor-2-substituted ketolide derivatives |
| 06/07/2001 | WO2001040240A2 Mono- and disaccharide derivatives |
| 06/07/2001 | WO2001040232A1 Chlorophyll and bacteriochlorophyll esters, and their preparation |
| 06/07/2001 | WO2001040231A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 06/07/2001 | WO2001040228A1 Carbapenem compounds, use of the same and intermediates thereof |
| 06/07/2001 | WO2001040222A1 Substituted isoxazolines and their use as antibacterial agents |
| 06/07/2001 | WO2001040216A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | WO2001040204A1 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient |
| 06/07/2001 | WO2001040198A2 Macrocyclic hydroxamic acid derivatives and their use as antimicrobial agents |
| 06/07/2001 | WO2001040194A1 Stilbene derivatives, their preparation and their use as antiviral agents |
| 06/07/2001 | WO2001040190A1 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
| 06/07/2001 | WO2001040189A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 06/07/2001 | WO2001039812A1 A bioabsorbable drug delivery system |
| 06/07/2001 | WO2001039803A2 Interleukin-1 muteins useful as vaccine adjuvants |
| 06/07/2001 | WO2001039802A1 Chimeric flavivirus vaccines |
| 06/07/2001 | WO2001039797A2 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus |
| 06/07/2001 | WO2001039786A2 New uses of suppressive macrophage activation factors |
| 06/07/2001 | WO2001039769A1 Hypoglycemics comprising organic zinc (ii) complexes |
| 06/07/2001 | WO2001039739A1 Retinaldehyde combination with antifungal activity |
| 06/07/2001 | WO2001039724A2 Phosphonate compounds |
| 06/07/2001 | WO2001039720A2 Dna polymerase inhibitors, mikanolide and dihydromikanolide |
| 06/07/2001 | WO2001039582A1 Use of a buffer to prevent candida albicans infections on the skin |
| 06/07/2001 | WO2001032865A8 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 06/07/2001 | WO2001028557B1 Cannabimimetic indole derivatives |
| 06/07/2001 | WO2001025213A3 Pyrrolo imidazole derivatives and their use as medicaments |
| 06/07/2001 | WO2001011971B1 Natural, anti-bacterial, anti-inflammation, anti-virus, anti-herpes cream |
| 06/07/2001 | WO2001010894A3 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 06/07/2001 | WO2001007612A3 Receptors and associated proteins |
| 06/07/2001 | WO2000072823A8 Preparations for the application of anti-inflammatory agents |
| 06/07/2001 | WO1999063940A3 INHIBITORS OF H+K+-ATPase |
| 06/07/2001 | US20010002998 Over-coated chewing gum formulations including tableted center |
| 06/07/2001 | DE19948434A1 Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine Substance library containing bicyclic imidazo-5-amines and / or bicyclic imidazo-3-amine |
| 06/07/2001 | CA2747954A1 Phosphonate compounds |
| 06/07/2001 | CA2393325A1 Infectious clones |
| 06/07/2001 | CA2393115A1 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses |
| 06/07/2001 | CA2393056A1 New dna polymerase inhibitors, mikanolide and dihydromikanolide |
| 06/07/2001 | CA2393047A1 6-o-methylerythromycin a crystal form iii |
| 06/07/2001 | CA2393041A1 Method for obtaining nucleic acids from an environment sample, resulting nucleic acids and use in synthesis of novel compounds |
| 06/07/2001 | CA2392989A1 Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| 06/07/2001 | CA2392979A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline crystal |
| 06/07/2001 | CA2392948A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 06/07/2001 | CA2392931A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | CA2392906A1 Pseudomonas aeruginosa antigens |
| 06/07/2001 | CA2392895A1 Streptococcus pneumoniae antigens |
| 06/07/2001 | CA2392853A1 Hbv sequences |
| 06/07/2001 | CA2392717A1 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | CA2392504A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 06/07/2001 | CA2392102A1 Use of a buffer to prevent candida albicans infections on the skin |
| 06/07/2001 | CA2391402A1 Masp-3, a complement-fixing enzyme, and uses for it |
| 06/07/2001 | CA2390786A1 Compositions and methods for the treatment of immune related diseases |
| 06/07/2001 | CA2390415A1 New uses of suppressive macrophage activation factors |
| 06/07/2001 | CA2390349A1 Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease |
| 06/07/2001 | CA2390088A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/06/2001 | EP1104811A1 HBV sequences |
| 06/06/2001 | EP1104809A1 Process for producing alpha-interferon |
| 06/06/2001 | EP1104767A1 Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups |
| 06/06/2001 | EP1104760A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104759A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104755A1 Process for the preparation of (S)-N-tertbutyl-1,2,3,4- tetrahydroisoquinoline-3-carboxamide |
| 06/06/2001 | EP1104676A1 Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| 06/06/2001 | EP1104470A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 06/06/2001 | EP1104465A1 14400 receptor, a g-protein coupled receptor |
| 06/06/2001 | EP1104456A1 Engineered antigen-presenting cells expressing an array of antigens and uses thereof |
| 06/06/2001 | EP1104446A1 Biologically active fraction of vegetable melanin, process for its production and its use |
| 06/06/2001 | EP1104440A1 A g-protein coupled 7tm receptor (axor-1) |
| 06/06/2001 | EP1104437A2 Antimicrobial peptides isolated from the skin of american frogs |
| 06/06/2001 | EP1104436A2 Ss-l-2'-deoxy-nucleosides for the treatment of hepatitis b virus |
| 06/06/2001 | EP1104422A1 Phenyl xanthine derivatives |
| 06/06/2001 | EP1104420A1 Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors |
| 06/06/2001 | EP1104412A1 Tace inhibitors |
| 06/06/2001 | EP1104408A2 Drug targeting |
| 06/06/2001 | EP1104403A1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 06/06/2001 | EP1104310A1 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response |